Syndax Pharmaceuticals

This large, late-stage study is testing whether adding an experimental drug called revumenib to standard chemotherapy works better than chemotherapy alone for adults newly diagnosed with a specific genetic type of acute myeloid leukemia (AML). The goal is to see if the combinatio…

This study is testing a new oral medication called revumenib for people with acute leukemias that have come back or not responded to standard treatments. The first part of the study aims to find the safest and most effective dose. The second part will test how well the drug works…

This study is testing the safety and early effectiveness of a new oral drug, SNDX-5613, when given alongside standard intensive chemotherapy to adults newly diagnosed with a fast-growing blood cancer called acute myeloid leukemia (AML). The trial is specifically for people whose …

This study is testing whether an investigational drug called axatilimab can slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. About 135 adults with IPF will receive either the drug or a placebo for 26 weeks to see …